Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06655246 · ClinicalTrials.gov registry record · Phase 1

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

A Phase 1 study of Gastrointestinal Stromal Tumor (GIST) and Gastrointestinal Stromal Neoplasm, sponsored by Kura Oncology.

Recruiting
Registry status
Phase 1
Development phase
157
Enrollment target
20
Study locations

NCT06655246 is a Phase 1 study of Gastrointestinal Stromal Tumor (GIST) and Gastrointestinal Stromal Neoplasm that is actively recruiting participants, run by Kura Oncology. The registered enrollment target is 157 participants, roughly in line with the 168-participant average among 6 other Gastrointestinal Stromal Tumor (GIST) trials with a reported enrollment target. The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06655246, a Phase 1 study of Gastrointestinal Stromal Tumor (GIST) and Gastrointestinal Stromal Neoplasm, is actively recruiting participants, sponsored by Kura Oncology.

RECRUITING
Registry status
Phase 1
Development phase
157 participants
Enrollment target
20
Study locations

Study Summary

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.

Conditions Studied

Gastrointestinal Stromal Tumor (GIST) Gastrointestinal Stromal Neoplasm Gastrointestinal Stromal Cancer Gastrointestinal Stromal Tumor, Malignant Gastrointestinal Stromal Cell Tumors

Interventions

  • DRUG ziftomenib
  • DRUG imatinib mesylate

Study Locations (20)

California

  • University of California, San Diego - La Jolla
  • University of Southern California - Los Angeles
  • University Of California, Irvine - Orange
  • Stanford Cancer Institute - Palo Alto
  • UCLA Santa Monica Medical Center - Santa Monica

Colorado

  • University of Colorado Cancer Center - Aurora
  • Sarah Cannon Research Institute - Denver

Florida

  • Mayo Clinic Cancer Center - Jacksonville
  • University of Miami - Miami

Massachusetts

  • Massachusetts General Hospital - Boston
  • Harvard University - Boston

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Mayo Clinic Cancer Center - Phoenix

Connecticut

  • Yale University School of Medicine - New Haven

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 157 participants
Start Date 2025-03-27
Est. Completion 2028-12
Phase Phase 1

Sponsor

Kura Oncology

14 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06655246

The ClinicalTrials.gov registry entry for NCT06655246 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 168-participant average among 6 other Gastrointestinal Stromal Tumor (GIST) trials with a reported enrollment target. The listed sponsor is Kura Oncology, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Gastrointestinal Stromal Tumor (GIST) appearing as the primary indexed condition, and to 2 interventions - of which ziftomenib is the first listed.

NCT06655246 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT06655246 about?

NCT06655246 is a clinical study titled "A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)". In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.

What is the current status of trial NCT06655246?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 157 participants. The study started on 2025-03-27. Estimated completion is 2028-12.

What conditions does trial NCT06655246 study?

This clinical trial studies the following conditions: Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors.

What interventions are being tested in trial NCT06655246?

The interventions under investigation include: ziftomenib (DRUG), imatinib mesylate (DRUG).

Who is sponsoring clinical trial NCT06655246?

This trial is sponsored by Kura Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06655246 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastrointestinal Stromal Tumor (GIST)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastrointestinal Stromal Tumor (GIST)

All registered trials for this condition

Gastrointestinal Stromal Neoplasm

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.